REG - Hemogenyx Pharma Plc - CBR Expanded to Treatment of Cancer

Hemogenyx PharmaceuticalsAnnouncement

27/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231127:nRSa6697Ua&default-theme=true

RNS Number : 6697U  Hemogenyx Pharmaceuticals PLC  27 November 2023

27 November 2023

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

CBR Expanded to Treatment of Cancer

Chimeric Bait Receptor-programmed macrophages show promise for treatment of
Non-Hodgkin Lymphoma

 

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group
developing new therapies and treatments for blood diseases, is pleased to
announce that its Chimeric Bait Receptor ("CBR") platform can potentially be
used in the treatment of cancers, in addition to the viral diseases
extensively reported by the Company to date.

The Company has demonstrated that human macrophages, a type of immune cells,
programmed with a purpose designed CBR, were able to eliminate Non-Hodgkin
Lymphoma ("NHL") derived cells with high efficiency in vitro. This result
suggests that the Company may be able to develop an efficient treatment for
people suffering from relapsed and/or refractory stage III/IV metastasized
NHL. In addition, based on data derived from its testing of CBR in connection
with NHL, the Company has reason to believe that the newly designed CBR
construct can be adapted to target several solid tumours such as epithelial
ovarian cancer as well as certain carcinomas.

The Company has been able to speed up its R&D efforts dramatically by
using Artificial Intelligence ("AI") based protein structure/interaction
simulations and in-house synthesis of messenger RNA ("mRNA"). AI tools allow
the Company's scientists to triage variants of CBR constructs rapidly in order
to select those with the greatest likelihood of success, while in-house mRNA
synthesis facilitates the building of CBR constructs in a matter of just days.

Moreover, the Company has previously reported that it is testing CBR against
live infectious SARS-Cov-2, the virus causing COVID-19. The Company has
received preliminary results of tests of CBR against this live infectious
virus. The results show that human macrophage cells programmed with CBR
against SARS-CoV-2 are effective in in vitro experiments. These tests are
being conducted by an external team of scientists in a biological level three
("BSL-3") facility. Additional work will be conducted to further optimize the
method of application of cells programmed with CBR, as well as to obtain
results in vivo (i.e., in a live animal model).

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented: "This is an exciting breakthrough in proving the versatility of
our CBR platform, greatly widening its potential use against cancers, in
addition to the original pursuit of combatting viral infections. We are
extremely pleased to see that CBR can potentially be used to develop new
treatments for cancers such as NHL, as well as potentially for solid tumours,
which are a significant challenge for existing therapies. We have also made
meaningful advances in proving CBR's potential viability in treating COVID-19
and other viruses. We are hugely encouraged by these recent developments, and
I am proud of Hemogenyx Pharmaceuticals' team of scientists who achieved this
leap forward."

 

About NHL

NHL is a subtype of cancers called lymphomas that develop in the lymph system.
NHL develops predominantly in adults, although children can also suffer from
this disease. NHL is the 11(th) most common cancer in humans, with roughly
540,000 new cases diagnosed globally and an estimated 260,000 deaths per year.
In the US, NHL is estimated to affect 80,550 people, with 20,180 deaths
resulting from this cancer in 2023 alone. The successful development of a new
therapy for NHL would have a major impact on treatment and survival rates for
the disease.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement.

The person responsible for arranging for the release of this announcement on
behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder.

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

The Company is a pre-clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune disease and to bring
the curative power of bone marrow transplantation to a greater number of
patients suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and complementary
product candidates, as well as a platform technology that it uses as an engine
for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCLQLFLXFLFFBD